A Study to Evaluate the Effect of Gastric pH on Acalabrutinib Pharmacokinetics (PK) in Healthy Adult Participants

Sponsor

Acerta Pharma BV (Industry)

Overall Status

Completed

CT.gov ID

NCT04905043

Collaborator

(none)

Enrollment

Location

Arm

1.2

Actual Duration (Months)

9.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study will evaluate the effect of gastric pH on acalabrutinib pharmacokinetics in healthy participants.

Condition or Disease	Intervention/Treatment	Phase
Healthy Volunteers	Drug: Acalabrutinib Drug: SmartPill®	Phase 1

Detailed Description

This is a 2-period study done under fasting conditions. Participants will receive an oral wireless motility/pH capsule (SmartPill®) followed immediately by a single 100 mg oral dose of acalabrutinib on Day 1 of Period 1 and Period 2 (ie, Day 1 and Day 4, respectively). There will be 72 hours of washout between Day 1 dosing of each period. Participants will be contacted approximately 14 days after the last dose of study drug for adverse events.

Study Design

Study Type:

Interventional

Actual Enrollment :

12 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase 1, Single-center, Open-label, Fixed-sequence, 2-period Study in Healthy Adult Subjects to Evaluate the Effect of Gastric pH on Acalabrutinib Pharmacokinetics

Actual Study Start Date :

Jun 3, 2016

Actual Primary Completion Date :

Jul 11, 2016

Actual Study Completion Date :

Jul 11, 2016

Arms and Interventions

Arm	Intervention/Treatment
Experimental: SmartPill® + Acalabrutinib Participants will receive 1 SmartPill® capsule followed immediately by a single oral dose of acalabrutinib 100 mg capsule on Day 1 (Period 1) and Day 4 (Period 2). There will be 72 hours of washout between acalabrutinib dosing of each period.	Drug: Acalabrutinib Participants will receive a single oral dose of acalabrutinib 100 mg capsule on Day 1 (Period 1) and Day 4 (Period 2). Other Names: ACP-196 Drug: SmartPill® Participnats will receive a single oral dose of wireless motility/pH capsule (SmartPill®) on Day 1 (Period 1) and Day 4 (Period 2).

Arm

Intervention/Treatment

Experimental: SmartPill® + Acalabrutinib

Participants will receive 1 SmartPill® capsule followed immediately by a single oral dose of acalabrutinib 100 mg capsule on Day 1 (Period 1) and Day 4 (Period 2). There will be 72 hours of washout between acalabrutinib dosing of each period.

Drug: Acalabrutinib

Participants will receive a single oral dose of acalabrutinib 100 mg capsule on Day 1 (Period 1) and Day 4 (Period 2).

Other Names:

ACP-196

Drug: SmartPill®

Participnats will receive a single oral dose of wireless motility/pH capsule (SmartPill®) on Day 1 (Period 1) and Day 4 (Period 2).

Outcome Measures

Primary Outcome Measures

Effect of Gastric pH and Emptying Rate on Acalabrutinib PK Parameters (Area Under Concentration-time Curve [AUC] From Time 0 to Last Measurable Concentration, AUC From Time 0 to Infinity, Maximum Observed Plasma Concentration [Cmax], Time to Reach Cmax) [0, 3, 8, and 17 minutes post-ingestion event time (IET) in Periods 1 and 2]
Area Under the Plasma Concentration-time Curve From Time 0 to Time of Last Measurable Concentration (AUC0-last) of Acalabrutinib [pre-dose; and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose in Periods 1 and 2]
Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of Acalabrutinib [pre-dose; and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose in Periods 1 and 2]
Maximum Observed Plasma Concentration (Cmax) of Acalabrutinib [pre-dose; and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose in Periods 1 and 2]

Secondary Outcome Measures

Percent of AUC0-inf Extrapolated (AUC%extrap) of Acalabrutinib [pre-dose; and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose in Periods 1 and 2]
Area Under the Plasma Concentration-time Curve From Time 0 to 6 Hours (AUC0-6h) of Acalabrutinib [pre-dose; and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose in Periods 1 and 2]
Area Under the Plasma Concentration-time Curve From Time 0 to 12 Hours (AUC0-12h) of Acalabrutinib [pre-dose; and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose in Periods 1 and 2]
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Acalabrutinib [pre-dose; and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose in Periods 1 and 2]
Apparent Terminal Elimination Rate Constant (λz) of Acalabrutinib [pre-dose; and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose in Periods 1 and 2]
Apparent Terminal Elimination Half-life (T1/2) of Acalabrutinib [pre-dose; and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose in Periods 1 and 2]
Apparent Total Plasma Clearance (CL/F) of Acalabrutinib [pre-dose; and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose in Periods 1 and 2]
Apparent Volume of Distribution (Vz/F) of Acalabrutinib [pre-dose; and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose in Periods 1 and 2]
Incidences of Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) [Day 1 through 14 days after the last dose (approximately 1 month)]
Incidences of Abnormal Vital Signs and Physical Examinations Reported as TEAEs [Day 1 to Day 5 for each participant]
Incidences of Abnormal Electrocardiograms (ECGs) Reported as TEAEs [Day 1 to Day 5 for each participant]
Incidences of Abnormal Clinical Laboratory Parameters Reported as TEAEs [Day 1 to Day 5 for each participant]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 65 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Continuous nonsmoker who has not used nicotine-containing products for >= 3 months before the first dose.
Body mass index (BMI) >= 18.0 and <= 32.0 kg/m^2 at screening.
Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs, or ECGs, as deemed by the principal investigator. Liver function tests, and serum bilirubin, must be <= upper limit of normal range (ULN) at screening.
Minimum of 1 bowel movement per day for >= 3 months before enrollment.
Women must be of non-childbearing status and must have negative serum pregnancy test results.
Men of reproductive potential to follow protocol defined contraception methods.

Exclusion Criteria:

Participant is mentally or legally incapacitated, or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
Participant has any of the following contraindications for the SmartPill: A history of gastric bezoars, swallowing disorder, suspected or known strictures, fistulas or physiological/mechanical gastrointestinal (GI) obstruction, history of GI surgery within 3 months of administration, severe dysphagia to food or pills, Crohn's disease or diverticulitis, cardiac pacemakers or other implanted electromedical devices.
History or presence of alcoholism or drug abuse within the past 2 years before screening
History of bleeding diathesis
History of gastric motility disorder for example delayed gastric emptying, dumping syndrome, or irritable bowel disease.
History of constipation within the last year before enrollment
Currently experiencing, or experienced within 2 weeks of enrollment, Grade 2 diarrhea
Women who are pregnant or breastfeeding
Positive urine drug or alcohol results at screening or check-in
Positive urine cotinine at screening.
Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).
Seated blood pressure is < 90/40 mmHg or > 140/90 mmHg at screening.
Seated heart rate is lower than 40 bpm or higher than 99 bpm at screening.
Have been on a diet incompatible with the on study diet, in the opinion of the principal investigator (PI), within the 28 days before the first dose of study drug, and throughout the study.
Unable to refrain from or anticipates the use of protocol defined medications.
History or presence of liver disease and clostridium difficile-associated diarrhea.